Prostate cancer trials recruiting in Kansas

All Prostate cancer trials nationally

Cities in Kansas

Recruiting trials in Kansas

• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
  NCT04729114 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Kansas: Wichita
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
  NCT03460977 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Kansas: Fairway, Kansas City, Overland Park, Westwood
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT07225946 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kansas: Wichita
• A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT06533644 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Kansas: Wichita
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
  NCT07213674 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Westwood
• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06764485 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Westwood, Wichita
• AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
  NCT07285694 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Kansas: Fairway
• An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
  NCT07206056 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Kansas: Wichita
• An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
  NCT05939414 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Kansas: Kansas City
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Kansas: Garden City, Great Bend, Leavenworth, Pittsburg
• DESTINY-PANTUMOUR04
  NCT07124000 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: All (male and female) · Kansas: Topeka
• HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
  NCT03802851 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Kansas: Kansas City
• Integrated Cancer Repository for Cancer Research
  NCT02012699 · Phase: Not specified · Ages: 19 Years to 110 Years · Sex: All (male and female) · Kansas: Overland Park
• Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
  NCT06780670 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Kansas: Kansas City
• PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
  NCT06274047 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Kansas City
• Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
  NCT06056830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Wichita
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
  NCT03678025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Kansas City, Olathe, Overland Park, Westwood
• Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
  NCT06855277 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: Male · Kansas: Kansas City
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
  NCT04221542 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · Kansas: Merriam
• Study of AZD0754 in Participants With Metastatic Prostate Cancer
  NCT06267729 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 130 Years · Sex: Male · Kansas: Westwood
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
  NCT05489211 · Phase: Phase 2 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Kansas: Kansas City
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
  NCT07745361 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Kansas: Kansas City
• TERPS Trial for de Novo Oligometastic Prostate Cancer
  NCT05223803 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · Kansas: Kansas City
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kansas: Kansas City, Olathe, Overland Park, Topeka
• Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
  NCT05946213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Kansas City, Lawrence, Olathe, Overland Park
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
  NCT06931340 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Hays, Lawrence, Olathe, Overland Park
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  NCT03866382 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kansas: Chanute, Dodge City, El Dorado, Fairway
• Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
  NCT04423211 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · Kansas: Garden City, Great Bend, Pittsburg
• TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  NCT07190300 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · Kansas: Westwood, Wichita
• Vitamin D for Prostate Endocrine Therapy
  NCT05838716 · Phase: Phase 3 · Ages: 50 Years and older · Sex: Male · Kansas: Kansas City, Overland Park, Topeka, Westwood